Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2
Manuela Di Fusco, Mary M. Moran, Alejandro Cané, et al.
Journal of Medical Economics (2021) Vol. 24, Iss. 1, pp. 1248-1260
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies
Manuela Di Fusco, Jay Lin, Shailja Vaghela, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 4, pp. 435-451
Open Access | Times Cited: 82
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, et al.
Cochrane library (2022) Vol. 2022, Iss. 6
Open Access | Times Cited: 40
Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study
Amita Ketkar, Vincent J. Willey, Michael Pollack, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 8, pp. 1103-1118
Open Access | Times Cited: 24
Immunocompromised individuals are at increased risk of COVID‐19 breakthrough infection, hospitalization, and death in the post‐vaccination era: A systematic review
Jola Bytyci, Yuxin Ying, Lennard Y. W. Lee
Immunity Inflammation and Disease (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 9
Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023–2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach
Ryan E. Wiegand, Owen Devine, Megan J. Wallace, et al.
Vaccine (2025) Vol. 49, pp. 126808-126808
Closed Access | Times Cited: 1
Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study
Naomi J. Patel, Xiaosong Wang, Xiaoqing Fu, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 58, pp. 152108-152108
Open Access | Times Cited: 37
Breakthrough SARS – CoV ‐2 Infections in Patients With Immune‐Mediated Disease Undergoing B Cell–Depleting Therapy: A Retrospective Cohort Analysis
Cassandra Calabrese, E. Kirchner, M. Elaine Husni, et al.
Arthritis & Rheumatology (2022) Vol. 74, Iss. 12, pp. 1906-1915
Open Access | Times Cited: 33
Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: A cohort study of 28 million people in France
Laura Semenzato, Jérémie Botton, Jérôme Drouin, et al.
The Lancet Regional Health - Europe (2022) Vol. 19, pp. 100441-100441
Open Access | Times Cited: 27
Immunizing the imperfect immune system
Jessica Durkee-Shock, Michael D. Keller
Annals of Allergy Asthma & Immunology (2022) Vol. 129, Iss. 5, pp. 562-571.e1
Open Access | Times Cited: 26
COVID-19 and Inborn Errors of Immunity
Ottavia M. Delmonte, Riccardo Castagnoli, Luigi D. Notarangelo
Physiology (2022) Vol. 37, Iss. 6, pp. 290-301
Open Access | Times Cited: 25
The effect of HIV on COVID-19 vaccine responses
Itzchak Levy, Galia Rahav
Current Opinion in HIV and AIDS (2023) Vol. 18, Iss. 3, pp. 135-141
Closed Access | Times Cited: 16
Factors Associated With an Electronic Health Record–Based Definition of Postacute Sequelae of COVID-19 in Patients With Systemic Autoimmune Rheumatic Disease
Naomi J. Patel, Xiaosong Wang, Lin Miao, et al.
The Journal of Rheumatology (2024) Vol. 51, Iss. 5, pp. 529-537
Open Access | Times Cited: 5
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program
Leanne P. M. van Leeuwen, Marloes Grobben, Corine H. GeurtsvanKessel, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort
Paul Loubet, Linda Wittkop, Läétitia Ninove, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 3, pp. 388.e1-388.e8
Open Access | Times Cited: 18
Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases
Naomi J. Patel, Claire Cook, Kathleen M.M. Vanni, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 4, pp. 565-573
Open Access | Times Cited: 18
Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs
Tafadzwa Dzinamarira, Nigel Tungwarara, Itai Chitungo, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 252-252
Open Access | Times Cited: 17
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy
Daniel Sidler, Alexander Born, Simeon Schietzel, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002166-e002166
Open Access | Times Cited: 17
Categorization of COVID‐19 severity to determine mortality risk
Elizabeth M. Garry, Andrew R. Weckstein, Kenneth Quinto, et al.
Pharmacoepidemiology and Drug Safety (2022) Vol. 31, Iss. 7, pp. 721-728
Open Access | Times Cited: 17
Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cases: Defining Immunological Mechanisms for Vaccine Waning and Vaccine-Variant Mismatch
Benjamin Hewins, Motiur Rahman, Jesús F. Bermejo-Martín, et al.
Frontiers in Virology (2022) Vol. 2
Open Access | Times Cited: 17
COVID-19 Breakthrough Infections in Immune-Mediated Inflammatory Diseases: Data from the SUCCEED (Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases) Study
Jeremiah Tan, Sasha Bernatsky, Jennifer L. Lee, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 104-104
Open Access
Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies
G. Olivieri, Donato Amodio, Emma Concetta Manno, et al.
Vaccine (2025) Vol. 51, pp. 126853-126853
Open Access
Patients with systemic autoimmune rheumatic diseases remain at risk for hospitalisation for COVID-19 infection in the Omicron era (2022–2024): a retrospective cohort study
Naomi J. Patel, Shruthi Srivatsan, Emily Kowalski, et al.
RMD Open (2025) Vol. 11, Iss. 1, pp. e005114-e005114
Open Access
Viral and host factors associated with SARS-CoV-2 disease severity in Georgia, USA
Ludy R Carmola, Allison Dorothy Roebling, Dara Khosravi, et al.
PLoS ONE (2025) Vol. 20, Iss. 4, pp. e0317972-e0317972
Open Access
COVID-19 infection in inborn errors of immunity and their phenocopies: a systematic review and meta-analysis
Saba Fekrvand, Kiarash Saleki, Hassan Abolhassani, et al.
Infectious Diseases (2025), pp. 1-35
Closed Access
SARS-CoV-2 Vaccines and Multiple Sclerosis
Tobias Monschein, Tobias Zrzavy, Paulus Rommer, et al.
Neurology Neuroimmunology & Neuroinflammation (2025) Vol. 12, Iss. 3
Closed Access
Page 1 - Next Page

Scroll to top